Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Chu HY, Englund JA, Starita LM, Famulare M, Brandstetter E, Nickerson DA, Rieder MJ, Adler A, Lacombe K, Kim AE, Graham C, Logue J, Wolf CR, Heimonen J, McCulloch DJ, Han PD, Sibley TR, Lee J, Ilcisin M, Fay K, Burstein R, Martin B, Lockwood CM, Thompson M, Lutz B, Jackson M, Hughes JP, Boeckh M, Shendure J, Bedford T; Seattle Flu Study Investigators. Early detection of Covid-19 through a citywide pandemic surveillance platform. N Engl J Med. 2020 Jul 9;383(2):185-187. doi: 10.1056/NEJMc2008646. Epub 2020 May 1. PubMed
Smith ER, Fry AM, Hicks LA, Fleming-Dutra KE, Flannery B, Ferdinands J, Rolfes MA, Martin ET, Monto AS, Zimmerman RK, Nowalk MP, Jackson ML, McLean HQ, Olson SC, Gaglani M, Patel MM. Reducing antibiotic use in ambulatory care through influenza vaccination. Clin Infect Dis. 2020 Apr 23. pii: ciaa464. doi: 10.1093/cid/ciaa464. [Epub ahead of print]. PubMed
Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, Jentz C, Northrup GR, Mahmud A, Reingold AL, Petersen M, Jewell NP, Young S, Bellows J. Incidence, clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and Washington, United States: a prospective cohort study. medRxiv. April 16, 2020.doi: https://doi.org/10.1101/2020.04.12.20062943.
Balasubramani GK, Nowalk MP, Sax TM, Suyama J, Bobyock E, Rinaldo CR Jr, Martin ET, Monto AS, Jackson ML, Gaglani MJ, Flannery B, Chung JR, Zimmerman RK. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 Apr 16. doi: 10.1111/irv.12741. [Epub ahead of print]. PubMed
Tenforde MW, Chung J, Smith ER, Talbot HK, Trabue CH, Zimmerman RK, Silveira FP, Gaglani M, Murthy K, Monto AS, Martin ET, McLean HQ, Belongia EA, Jackson LA, Jackson ML, Ferdinands JM, Flannery B, Patel MM. Influenza vaccine effectiveness in inpatient and outpatient settings in the United States, 2015 - 2018. Clin Infect Dis. 2020 Apr 9. pii: 5818114. doi: 10.1093/cid/ciaa407. [Epub ahead of print]. PubMed
Jackson ML, Hart GR, McCulloch DJ, Adler A, Brandstetter E, Fay K, Han P, Lacombe K, Lee J, Sibley T, Nickerson DA, Rieder M, Starita L, Englund JA, Bedford T, Chu H, Famulare M, Seattle Flu Study Investigators. Effects of weather-related social distancing on city-scale transmission of respiratory viruses. medRxiv. March 03, 2020. doi: https://doi.org/10.1101/2020.03.02.20027599.
Satizabal CL, Aparicio HJ, Adams HHH, Reiner AP, Longstreth WT Jr, Fornage M, Tracy RP, Lopez O, Psaty BM, Levy D, Seshadri S, Bis JC. Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. Neurology. 2020 Jan 21;94(3):e254-e266. doi: 10.1212/WNL.0000000000008682. Epub 2019 Dec 9. PubMed
Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(7):177-182. doi: 10.15585/mmwr.mm6907a1. PubMed
Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Chung JR, Spencer S, Fry AM, Flannery B. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2021 Apr 8;72(7):1147-1157. doi: 10.1093/cid/ciaa102. PubMed
Ahmed F, Kim S, Nowalk MP, King JP, VanWormer JJ, Gaglani M, Zimmerman RK, Bear T, Jackson ML, Jackson LA, Martin E, Cheng C, Flannery B, Chung JR, Uzicanin A. Paid leave and access to telework as work attendance determinants during acute respiratory illness, United States, 2017-2018. Emerg Infect Dis. 2020;26(1). doi: 10.3201/eid2601.190743. PubMed
Vaccines given in last 20 years could prevent 50 million deaths in 112 countries
Answers to 4 questions about COVID-19 and this season's flu, from KPWHRI's Michael Jackson, PhD, MPH.
In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Verywell Health, Jan. 13, 2021
KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.
WebMD, Sept. 2, 2020